Private Advisor Group LLC lowered its position in Regeneron (NASDAQ:REGN) by 14.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,981 shares of the biopharmaceutical company’s stock after selling 496 shares during the quarter. Private Advisor Group LLC’s holdings in Regeneron were worth $1,027,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. CIBC Asset Management Inc lifted its holdings in Regeneron by 5.4% in the 4th quarter. CIBC Asset Management Inc now owns 12,318 shares of the biopharmaceutical company’s stock worth $4,631,000 after buying an additional 634 shares in the last quarter. Norinchukin Bank The increased its position in shares of Regeneron by 7.7% in the 4th quarter. Norinchukin Bank The now owns 6,160 shares of the biopharmaceutical company’s stock worth $2,316,000 after purchasing an additional 441 shares during the last quarter. Guggenheim Capital LLC increased its position in shares of Regeneron by 35.4% in the 4th quarter. Guggenheim Capital LLC now owns 217,333 shares of the biopharmaceutical company’s stock worth $81,707,000 after purchasing an additional 56,829 shares during the last quarter. Dynasty Wealth Management LLC bought a new stake in shares of Regeneron in the 4th quarter worth about $313,000. Finally, Senzar Asset Management LLC increased its position in shares of Regeneron by 46.8% in the 4th quarter. Senzar Asset Management LLC now owns 113,500 shares of the biopharmaceutical company’s stock worth $42,671,000 after purchasing an additional 36,200 shares during the last quarter. Hedge funds and other institutional investors own 66.38% of the company’s stock.
Several research firms have recently weighed in on REGN. Barclays set a $290.00 target price on shares of Regeneron and gave the stock a “sell” rating in a research report on Wednesday. Zacks Investment Research downgraded shares of Regeneron from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. BidaskClub downgraded shares of Regeneron from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 9th. Royal Bank of Canada dropped their target price on shares of Regeneron to $342.00 and set a “sector perform” rating for the company in a research report on Monday, May 7th. Finally, Credit Suisse Group set a $420.00 target price on shares of Regeneron and gave the stock a “buy” rating in a research report on Saturday, May 5th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have issued a buy rating to the company. Regeneron currently has an average rating of “Hold” and a consensus price target of $426.88.
In other news, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $350.02, for a total value of $700,040.00. Following the completion of the sale, the director now directly owns 14,000 shares of the company’s stock, valued at approximately $4,900,280. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director George L. Sing sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 9th. The stock was sold at an average price of $285.29, for a total transaction of $1,997,030.00. Following the completion of the sale, the director now directly owns 127,772 shares of the company’s stock, valued at $36,452,073.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,000 shares of company stock valued at $3,377,070. Company insiders own 12.42% of the company’s stock.
NASDAQ REGN opened at $294.61 on Friday. Regeneron has a 52 week low of $281.89 and a 52 week high of $543.55. The company has a quick ratio of 2.94, a current ratio of 3.59 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $31.80 billion, a price-to-earnings ratio of 21.97, a PEG ratio of 1.06 and a beta of 1.44.
Regeneron (NASDAQ:REGN) last posted its earnings results on Thursday, May 3rd. The biopharmaceutical company reported $4.67 EPS for the quarter, missing the consensus estimate of $5.08 by ($0.41). Regeneron had a return on equity of 29.92% and a net margin of 23.54%. The firm had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter last year, the company posted $2.92 EPS. Regeneron’s revenue for the quarter was up 14.6% on a year-over-year basis. equities analysts expect that Regeneron will post 17.2 earnings per share for the current year.
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron (NASDAQ:REGN).
Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.